Provides an intraocular drug delivery platform that integrates with intraocular lenses (IOLs) to release bimatoprost continuously for up to three years, treating glaucoma in patients undergoing cataract surgery. This system addresses patient non-adherence to topical medications, reducing the risk of disease progression and vision loss by ensuring consistent, long-term intraocular pressure control.
Funding
$123.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glaucoma patients undergoing cataract surgery often struggle with adherence to topical medication regimens, leading to inconsistent intraocular pressure control and increased risk of disease progression and vision loss. Current methods of drug delivery require consistent patient action, creating a need for solutions independent of patient behavior.
Solution
SpyGlass Pharma offers an intraocular drug delivery platform that integrates with intraocular lenses (IOLs) to provide continuous, long-term release of bimatoprost, targeting up to three years of therapy. The platform consists of dual pads securely attached to each haptic of the IOL, designed to elute medication consistently. Implanted during standard cataract surgery, the SpyGlass Pharma Drug Delivery Platform aims to ensure consistent intraocular pressure control, reducing the risk of glaucoma progression associated with patient non-adherence to topical medications.
Target Audience
The primary target audience includes cataract surgeons managing glaucoma patients who require consistent, long-term intraocular pressure control.
Features
- IOL-mounted drug delivery system for sustained release of bimatoprost
- Designed for implantation during routine cataract surgery using standard techniques
- Dual-pad haptic design for continuous elution of medication
- Targets consistent drug delivery for up to three years
- Addresses patient non-adherence to topical glaucoma medications
- Aims to reduce disease progression and vision loss associated with inconsistent IOP control